Apyx Medical Corporation (APYX)
Oxford Ledge is still expanding full research coverage of APYX. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Apyx Medical sells surgical aesthetic devices including Renuvion and the newly launched AYON body contouring system, with 2025 revenue of $52.8 million offset by ongoing operating losses.
SEC filings
- DEF 14A Proxy statement for shareholder vote 2026-06-26
- 8-K Entry into material agreement; Financial statements and exhibits 2026-06-17
- 8-K Other material event; Financial statements and exhibits 2026-05-21
- 8-K Other material event; Financial statements and exhibits 2026-05-14
- 8-K Other material event; Financial statements and exhibits 2026-05-11
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for APYX. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open APYX in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.